Journal
EUROPEAN JOURNAL OF HEART FAILURE
Volume 17, Issue 3, Pages 242-247Publisher
WILEY
DOI: 10.1002/ejhf.250
Keywords
Neutral endopeptidase 24; 11; Neprilysin; Enkephalinase; Angiotensin; Angiotensin converting enzyme; Natriuretic peptides; Bradykinin; Adrenomedullin; Heart failure; Neurohumoral; Neuroendocrine; Neurohormonal; Ejection fraction
Categories
Funding
- Novartis
Ask authors/readers for more resources
This review describes the role of neprilysin (also known as neutral endopeptidase or enkephalinase) in the degradation of natriuretic and other vasoactive peptides, including bradykinin and adrenomedullin. The initial development of neprilysin inhibitors, then angiotensin converting enzyme-neprilysin inhibitors and, most recently, the angiotensin receptor neprilysin inhibitor (ARNI) LCZ696 (sacubitril valsartan) as an extension of the nurohumoral basis for the treatment of heart failure is also summarised. Finally, the implications of the compelling benefits of LCZ696 compared with enalapril in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) is discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available